Suzhou Maitai Bio-Technology Co., Ltd.

The pharmacokinetics of a single oral dose of the test formulation T1 Maihuatinib tablet (specification: 80 mg/tablet, produced by Hangzhou Sino-US Huadong Pharmaceutical Co., Ltd.) and the test formulation T2 Maihuatinib tablets (specification: 20 mg/tablet, produced by Hangzhou Sino-US Huadong Pharmaceutical Co., Ltd.) in healthy adult subjects were studied in the fasting state, and the bioequivalence of the two oral preparations in the fasting state was evaluated.

1) Primary objective: To evaluate the efficacy of mehuatinib in the treatment of advanced non-small cell lung cancer with rare EGFR mutations. 2) Secondary objective: To evaluate the safety of mehuatinib in the treatment of advanced non-small cell lung cancer with rare EGFR mutations.

Primary objective: To evaluate the efficacy of mehuatinib 60mg or 80mg as first-line treatment for advanced non-small cell lung cancer with EGFR sensitive mutations. Secondary objective: To evaluate the safety of mehuatinib 60mg or 80mg as first-line treatment for advanced non-small cell lung cancer with EGFR sensitive mutations.